The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.
about
Predicting survival time in noncurative patients with advanced cancer: a prospective study in China.Physical activity and fatigue in breast cancer and multiple sclerosis: psychosocial mechanisms.Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma.Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.Serum albumin predicts survival in patients with hilar cholangiocarcinomaProgression-free survival: an important prognostic marker for long-term survival of small cell lung cancerSimplified Graded Baseline Symptom Assessment in Patients With Lung Cancer Undergoing First-Line Chemotherapy: Correlations and Prognostic Role in a Resource-Constrained SettingEnhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity.Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers.The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapyElevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinomaPrognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trialNeuromuscular electrical stimulation of the quadriceps in patients with non-small cell lung cancer receiving palliative chemotherapy: a randomized phase II study.Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression.First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma.Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer.Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapyModified glasgow prognostic score predicting high conversion ratio in opioid switching from oral oxycodone to transdermal fentanyl in patients with cancer painThe relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer.Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before ChemoirradiationHigh anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer.Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysisWheel Balanced Cancer Therapy for Longer Than 21 Days Can Have a Positive Effect on the Survival of Patients with Stage IV CancerA systematic review of the association between immunogenomic markers and cancer-related fatigueDevelopment and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy.Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer.A systematically structured review of biomarkers of dying in cancer patients in the last months of life; An exploration of the biology of dying.Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapyCorrelates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors.Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on quality of life: a cross-sectional study.Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer.A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancerComparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancerThe systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.
P2860
Q33576398-42470DA3-37AA-4DF6-89FD-28441C0B90F2Q33671860-FFBB9C90-7C97-4971-92B9-9484EA4413E7Q33684941-08D22F57-9430-4466-B0C5-995EEC911563Q33723662-4598228D-B12A-48F1-B005-24890B5F9561Q33726891-47BAEA2E-6A9B-4780-AE51-6481452012AAQ33728681-FA81D68B-3022-48AF-B462-8ECABF22C9CDQ33859585-8E6838B8-B541-456C-AA74-7E9A28AB5D8DQ34065499-5B252EF9-2BDD-49E0-9622-4814BD365EAFQ34079559-704BC98C-2373-4CA7-B771-B84294686DDDQ34084838-03AD5BF0-4A0C-40F8-8CF6-A74AF9BFF3E4Q34241072-E9E5B61B-8DD1-44F4-90FD-C1325C0C30CCQ34392042-7253E514-748B-4B10-A66E-8002DC392803Q34395838-B6FB78C8-4DE9-4584-922D-CCBC45700FE1Q34636595-9F17655D-DAB6-43A6-9A74-DABB64B5DBE5Q34747013-128837D4-45E5-4D74-AE22-AA908FD93EA7Q35081238-CFB053CC-EAF4-4B0B-A79D-F36298D64698Q35264807-47EA86EC-EAF0-47BD-8816-E30FE3E2A9E2Q35544697-19886952-C101-44EE-A110-DB023EDB7275Q35804538-7F103D6C-8F7F-44F8-B091-7AB3BFCA0883Q35851207-B91A3111-CF78-4F94-9022-AEBEB8F6A659Q35870860-E48B5806-656A-4769-BC55-FA3C62DB5E2AQ35954348-358A3A28-CB02-48BF-A049-EE8A0424FF5AQ35960578-E9A50D6B-E242-4D82-8073-8BA125676640Q36000203-DF1AEAD2-B36E-476E-B5E4-AD38A0BBB6BCQ36046192-175F2978-7C17-453F-AE2F-0DD5B16CA636Q36070272-92284601-EE13-4D42-B064-45D134DD273FQ36098741-514D747F-BFB0-4510-924E-2A1E6A2943DAQ36205922-C0FE415C-6EC1-458C-8309-8F87360B0D52Q36210250-F6833B98-7D0B-4234-AE44-A2EECA8F5381Q36336092-D7A96B05-FF6B-4053-8AA8-FE7F4493E471Q36338248-0221420A-A0E9-45C7-B40F-6DFC8493C794Q36449810-C16F80DE-0DE7-427A-9DB2-F77AF7B758A0Q36469182-14E7B9D2-2124-4DD5-8BF7-27FBA8DE3D4AQ36612753-D2A5E81C-178A-4D92-AC42-7686482856C7Q36613902-995F9449-546F-4BBC-93FE-51171532E1B8Q36615878-1C980D20-3298-47C3-93C9-740A7728B081Q36648454-CF448691-60DB-4BCB-87F3-4C73D3E9EDB3Q36695064-8155D511-3257-46BF-8B9C-4F075158D071Q36695683-81C0B064-8585-4138-9FF9-5509CEBE1C56Q36696573-B27775A0-D061-4F0C-AB51-269CD25A166B
P2860
The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
The systemic inflammatory resp ...... le non-small cell lung cancer.
@ast
The systemic inflammatory resp ...... le non-small cell lung cancer.
@en
type
label
The systemic inflammatory resp ...... le non-small cell lung cancer.
@ast
The systemic inflammatory resp ...... le non-small cell lung cancer.
@en
prefLabel
The systemic inflammatory resp ...... le non-small cell lung cancer.
@ast
The systemic inflammatory resp ...... le non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
The systemic inflammatory resp ...... ble non-small cell lung cancer
@en
P2093
C S McArdle
D J F Brown
L M Forrest
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600466
P407
P577
2002-07-01T00:00:00Z